A5027867889- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- RNA modifications and cancer
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cytokine Signaling Pathways and Interactions
- Cancer Genomics and Diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Synthesis and biological activity
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Polyomavirus and related diseases
- Sarcoma Diagnosis and Treatment
- Chemotherapy-related skin toxicity
- Eosinophilic Disorders and Syndromes
- BRCA gene mutations in cancer
- Cancer Treatment and Pharmacology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Multiple Myeloma Research and Treatments
- Pituitary Gland Disorders and Treatments
- Medical Imaging and Pathology Studies
- Ethics in Clinical Research
- Hair Growth and Disorders
- Neuroblastoma Research and Treatments
- Multiple and Secondary Primary Cancers
Centre Hospitalier Ibn Sina
2023
Central Michigan University
2016-2022
Ascension
2022
St. Mary's Medical Center
2018
HealthPartners
2016
University of Toledo
2010-2015
University of Toledo Medical Center
2010-2013
Abstract Purpose: Efficacy of MEK inhibitors in KRAS+ NSCLC may differ based on specific KRAS mutations and comutations. Our hypothesis was that docetaxel trametinib would improve activity specifically G12C NSCLC. Patients Methods: S1507 is a single-arm phase II study assessing the response rate (RR) with plus recurrent secondarily subset. The accrual goal 45 eligible patients, at least 25 mutation. design two-stage to rule out 17% RR, within overall population one-sided 3% level subset 5%...
Polycythemia vera is one of the chronic myeloproliferative diseases and very few patients present with its actual clinical manifestations. The most common findings are increased red cell mass an leukocyte count decreased erythropoietin. We a case where there was delay in diagnosis polycythemia because menorrhagia past. On admission, patient presented elevated white blood counts, erythropoietin low, then suspected. A bcr-abl test performed to rule out myelogenous leukemia. JAK2 mutation...
Henoch-Schonlein purpura (HSP) is an acute leukocytoclastic vasculitis that primarily affects children but also approximately 1% of adults. We discuss a case HSP started after pantoprazole ingestion. Clinical manifestation included terminal ileitis and rapidly progressing glomerulonephritis. To our knowledge, this the first reported secondary to The patient presented with renal failure requiring hemodialysis was initially unresponsive intravenous pulse steroids. treated mycophenolate...
9021 Background: KRAS+ NSCLC remains the most common genetically defined subset of NSCLC. Despite promising pre-clinical data, MEK inhibitors have failed to provide meaningful clinical benefit both as single agents and in combination with chemotherapy patients. Pre-clinical data suggest that efficacy differs based on specific KRAS mutations such G12C by status p53 or LKB1 mutations. We conducted a phase II study assess docetaxel plus trametinib patients genetic subsets. Methods: who had...
Studies have reported second malignancies occurring in patients with chronic myeloid leukemia (CML) or lymphoid (CLL). We discuss the case of a 77-year-old man diagnosed CLL who later developed CML. The was managed surveillance after diagnosis for 3 years and treated ibrutinib venetoclax. While on treatment venetoclax 4 months, patient had worsening leukocytosis shown via peripheral flow cytometry fluorescence situ hybridization, presence lineage cells positive BCR-ABL complete disappearance...
Docetaxel belongs to the taxane family of anti-cancer drugs, which are commonly used in non-small cell lung cancers. They stabilize microtubules by preventing depolymerization, resulting death. Pneumonitis is an uncommon side effect docetaxel. We report a case docetaxel induced hypersensitivity pneumonitis mimicking lymphangitic carcinomatosis patient with metastatic adenocarcinoma lung.
Post transplant lymphoproliferative disease (PTLD) is a rare but potentially fatal complication after solid organ transplantation. The risk of PTLD varies with type transplant, Epstein-Barr virus serostatus the donor and recipient, age, intensity immunosuppression. We report case 45-year-old man who developed aggressive 7 months receiving cadaveric renal transplant. He received 30 mg alemtuzumab intravenously intraoperatively as induction immunosuppression followed by maintenance tacrolimus...
Platinum-based antineoplastic drugs are widely used in the treatment of solid tumors. Carboplatin, a second generation platinum compound, was developed to have less nonhematologic toxicity, comparison with cisplatin. We report on 34-year-old woman breast cancer who gross hematuria after initiation carboplatin-based chemotherapy. To our knowledge, there very few cases reports carboplatin-associated hematuria.
Immune checkpoint inhibitors are rapidly becoming popular therapeutic options for patients suffering from a number of malignancies. Atezolizumab is programmed cell death ligand-1 inhibitor, and binding to this ligand decreases the ability tumor cells evade immune system, resulting in self-tolerance. While inhibition these molecules leads increased T-cell destruction cells, it also may lead autoimmune healthy cells. Neurotoxicity rare complication inhibitor therapy, facial palsy as...
Bortezomib with or without dexamethasone has been reported to be very effective and well tolerated in the treatment of AL amyloidosis. Commonly adverse effects are fatigue, nausea, vomiting, diarrhea, constipation, postural hypotension from autonomic neuropathy, peripheral thrombocytopenia anemia. Dyspnea rarely as an effect bortezomib therapy We reporting three case reports patients suffering amyloidodis, who had new onset acute dyspnea secondary that required drug discontinuation. There...
Objective: Anorexia nervosa (AN) is a severe psychiatric disorder, in which an individual suffers from weight loss, and disturbed physical psychosocial functioning. It was previously diagnosed reported Western countries but its prevalence on the rise Middle East country like Iran. This study aims to introduce patient with AN hyperprolactinoma. Methods: case report. A single, educated not currently employed 32-year-old female admitted chief complaint of locked knee, weakness, lethargy; she...
<p>Supplementary Figure 1. Progression-Free Survival and Overall in patients with cancers TP53 co-mutations, STK11 co-mutations.</p>
<div>Abstract<p>Purpose: Efficacy of MEK inhibitors in KRAS+ NSCLC may differ based on specific KRAS mutations and co-mutations. Our hypothesis was that docetaxel trametinib would improve activity specifically G12C NSCLC. Patients Methods: S1507 is a single arm phase II assessing the response rate (RR) with plus recurrent secondarily subset. The accrual goal 45 eligible patients at least 25 mutation. design 2-stage to rule out 17% RR, within overall population 1-sided 3% level...
<p>Supplementary Figure 1. Progression-Free Survival and Overall in patients with cancers TP53 co-mutations, STK11 co-mutations.</p>
Thalidomide is one of the immunomodulating agents used in current oncology practice. We present a case hemorrhagic rash induced by thalidomide patient with delta granule storage pool disease. The was getting for underlying myelofibrosis.
Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor, which used for non-small-cell lung cancer treatment. usually has favorable safety profile however; adverse events such as interstitial disease (ILD) have been reported in pivotal studies. ILD occurs weeks to months after initiating therapy with Erlotinib. We report case of induced presenting within 5 days treatment
Introduction: Neutrophilic leukocytosis has been seen in many solid non-hematological tumors producing G-CSF(granulocyte-colony secreting factor). However, few cases have reported worldwide of hepatocellular cancer (HCC) with neutrophilic leukocytosis. (1)(2) Case: 84 year old male patient presented failure to thrive and loss weight. No alcohol abuse. On examination there was tenderness right upper quadrant abdomen splenomegaly. Labs: Hb- 8.6gm/dl, RBC- 2.9 M/mcl,Hct-26.5%, WBC-17.2...
Abstract Background More than 70% of breast cancer patients develop endocrine-responsive disease with estrogen receptor (ER)-positive or progesterone receptor-positive tumors both [1] and require endocrine treatment either blockage ablation. The aromatase inhibitors are highly effective well-tolerated for postmenopausal cancer. However, their use is associated accelerated bone loss an increase in fracture risk(2, 3) Method Post menopausal early stage cancer( I II) which was ER and/or PR...